https://pepsreview.com/articles/glp-1-addiction-trials-move-beyond-obesity-alcohol-drug-cravings PepsReview en 2026-10-23 GLP-1, semaglutide, alcohol use disorder, opioid use disorder, addiction research, clinical trials, peptide research https://pepsreview.com/articles/glp-1-users-fragrance-spending-sensory-shift-study PepsReview en 2026-10-23 GLP-1, GLP-1 research, fragrance trends, gourmand fragrance, sensory reward, GLP-1 consumer behavior, olfactory research, peptide research news https://pepsreview.com/articles/cagrisema-women-redefine1-25-percent-weight-loss-analysis PepsReview en 2026-10-21 CagriSema, REDEFINE 1, Novo Nordisk, women weight loss, menopause, cagrilintide, semaglutide, obesity trial https://pepsreview.com/articles/compounded-tirzepatide-recalled-nationwide-over-sterility-concerns PepsReview en 2026-10-21 GLP-1 recall, compounded tirzepatide, Apothecary Pharma, FDA recall, Class II recall, sterility, compounding pharmacy https://pepsreview.com/articles/is-your-glp-1-real-fda-copycat-crackdown-buyer-checklist PepsReview en 2026-10-21 GLP-1 copycat drugs, FDA crackdown, compounded tirzepatide, compounded semaglutide, unapproved GLP-1, drug safety, peptide testing